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Children in TaiwanCommunity-acquired pneumonia is a common disease and
the leading cause of death among children worldwide. In
Taiwan, Streptococcus pneumoniae, Mycoplasma pneumo-
niae, and viruses are equally common etiologic pathogens in
healthy children with community-acquired pneumonia.1
Historically, pneumonia caused by Streptococcus pneumo-
niae usually resolved completely without destructive
sequelae in spite of intense inflammation during pneumo-
coccal infection. However, the incidence of complications of
pneumococcal pneumonia, including necrotizing pneumonia
and/or empyema, has increased among children in the past
decade.2 Before the use of pneumococcal conjugate vaccine
7 in Taiwan, serotype 14 was themost common serotype that
caused necrotizing pneumonia and/or empyema.2 Since
2009, there has been a shift from serotype 14 being the
predominant serotype to serotype 19A.3 The same shift
occurred for the genotype ST46, a clone associated with
necrotizing pneumonia and empyema,2,3 being the predom-
inant genotype previously to genotype ST320. Serotype 19A
ST320 pneumonia had a significantly higher risk of lung ne-
crosis and air leak.3 The evolution of serotype 19A ST320 into
a highly virulent strain with high-level resistance to anti-
microbial agents is a great challenge in treating pneumo-
coccal disease. The optimal pneumococcal conjugate
vaccine must contain serotype 19A to prevent this serious
complication in children in Taiwan and elsewhere.
M. pneumoniae is a common pathogen responsible for
pediatric community-acquired pneumonia, accounting for
10e40% of cases. The illness is usually self-limiting, with
symptoms lasting several weeks, but sometimes it causes
severe pneumonia. Although there is still insufficient evi-
dence to show that antibiotics are effective in children with
pneumonia caused by M. pneumoniae, macrolides are the
drug of choice for treating children with M. pneumoniae
infection.4 Since 2000, macrolide resistance in M. pneu-
moniae strains has been increasing since the report of
a pediatric patient infected by macrolide-resistant
M. pneumoniae in Japan. Disease caused by macrolide-
resistant M. pneumoniae has a longer duration of fever
than that caused by macrolide-susceptible M. pneumo-
niae.5 The mechanism of resistance to macrolides in1875-9572/$36 Copyright ª 2013, Taiwan Pediatric Association. Publish
http://dx.doi.org/10.1016/j.pedneo.2012.12.018M. pneumoniae frequently involves mutations in the 23S
rRNA including transitions of A2063G and A2064G. The
mutation at A2063G is more common than A2064G, but the
mutation at A2064G confers resistance to a broader spec-
trum of other antimicrobial agents. Wang et al reported
that M. pneumoniae was the most frequent cause of fatal
community-acquired pneumonia in a medical center in
Taiwan.6 A proportion of M. pneumoniae pneumonia was
noted to present with persistent fever, hypoxemia, and
radiographic deterioration in spite of macrolide usage.7
Pleural effusion, necrotizing pneumonitis, lung abscess,
bronchiolitis obliterans organizing pneumonia, and acute
respiratory distress syndrome have been reported in asso-
ciation with M. pneumoniae pneumonia in children.7 Severe
lung injury in M. pneumoniae pneumonia was presumed to
be a consequence of overproduction of cytokines and an
exuberant cell-mediated immune response. Clinical expe-
riences and animal models suggest that the use of both
antimicrobial therapy and immunomodulatory agents is
important to improve the outcome of severe M. pneumo-
niae pneumonia. In contrast, extracorporeal membrane
oxygenation therapy could be considered to treat patients
with acute respiratory distress syndrome caused by
M. pneumoniae.7 The percentage of macrolide-resistant
M. pneumoniae strains in Taiwan was 23% in a multicenter
study.5 Given the increase of macrolide-resistant M. pneu-
moniae in recent years, effective antimicrobial treatment
should be a critical component of managing severe cases of
macrolide-resistant strain infection. More studies to eval-
uate the optimal treatment in severe cases of M. pneu-
moniae pneumonia regardless of macrolide resistance are
warranted.
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